Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Aclaris Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 97 | 128 | +31 |
| Shares | 45.4M | 56.0M | +10.6M (+23.3%) |
| Value | $1.14B | $983.4M | −$161.4M (−14.1%) |
New holders (49)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (18)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Stenahm Asset Managment Ltd | 283,500 | $7.14M |
| EAM Investors, LLC | 205,295 | $5.17M |
| Pura Vida Investments, LLC | 175,799 | $4.43M |
| Tri Locum Partners LP | 164,199 | $4.14M |
| HRT Financial LP | 152,119 | $3.83M |
| EAM Global Investors LLC | 121,563 | $3.06M |
| Farallon Capital Management, L.L.C. | 100,000 | $2.52M |
| Parametric Portfolio Associates LLC | 84,276 | $2.12M |
| Marshall Wace, LLP | 36,612 | $923.0K |
| LMR Partners LLP | 26,974 | $680.0K |
| Jane Street Group, LLC | 24,302 | $612.0K |
| Creative Planning | 17,740 | $447.0K |
| Belvedere Trading LLC | 16,473 | $415.0K |
| Diametric Capital, LP | 11,038 | $278.0K |
| Squarepoint Ops LLC | 8,537 | $215.0K |
| Dorsey Wright & Associates | 6,110 | $154.0K |
| Maven Securities LTD | 2,605 | $66.0K |
| Federated Hermes, Inc. | 291 | $7.00K |